Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: A note of caution

Hormone Research

Volumn 71, Issue 1, 2009, Pages 38-44

  Alharbi, M ^a   Pinto, G ^a   Finidori, G ^a   Souberbielle, J C ^a   Guillou, F ^b   Gaubicher, S ^a   Le Merrer, M ^a   Polak, M ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Psychiat des Hop (Saint Maurice)   (France)

Author keywords

Bisphosphonates; Bone mineral density; Children; Delayed fracture healing; Osteogenesis imperfecta

Indexed keywords

CALCIUM; PAMIDRONIC ACID; PARACETAMOL; VITAMIN D;

ARTICLE; BODY HEIGHT; BONE DENSITY; BONE RADIOGRAPHY; CALCIUM BLOOD LEVEL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FRACTURE HEALING; FRACTURE NONUNION; HUMAN; LOCOMOTION; MALE; OCCUPATIONAL THERAPY; ORTHOPEDIC SURGERY; OSTEOGENESIS IMPERFECTA; PHYSIOTHERAPY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; AMINO ACIDS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FRACTURE HEALING; FRACTURES, BONE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OSTEOCALCIN; OSTEOGENESIS IMPERFECTA; PARATHYROID HORMONE; PROSPECTIVE STUDIES;

EID: 56749165385     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000173740     Document Type: Article

References (36)

1. Rauch R, Glorieux FH: Osteogenesis imperfecta. Lancet 2004;363:1377-1385.
2. Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M: The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta. Calcif Tissue Int 2003;72:103-112.
3. Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C: Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study. Joint Bone Spine 2005;72:313-318.
4. Lee YS, Low SL, Lim LA, Loke KY: Cyclic pamidronate infusion improves bone mineralization and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr 2001;160:641-644.
5. Rauch F, Travers R, Munns C, Glorieux FH: Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric. Analysis J Bone Miner Res 2004;19:1191.
6. Glorieux FH, Bishop NJ, Plotkin H, Chabot G Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
7. Allgrove J: Use of bisphosphonates in children and adolescents. J Pediatr Endocrinol Metab 2002;3:921-928.
8. Arikoski P, Silverwood B, Tillman V, Bishop NJ: Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy. Bone 2004;34:539-546.
9. Huaux JP, Lokietek W: Is APD a promising drug in the treatment of severe osteogenesis imperfecta. J Pediatr Orthop 1988;8:71-72.
10. Rauch F, Plotkin H, Zeitlin L, Glorieux FH: Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy. J Bone Miner Res 2003;18:610.
11. Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke TH: Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol 2005;35:511-517.
12. Rauch F, Travers R, Glorieux FH: Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endocrinol Metab 2005;91:511-516.
13. Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH: Effect of intravenous pamidronate therapy on functional ability and level of ambulation in children with osteogenesis imperfecta. J Pediatr 2006;148:456-460.
14. Astrom E, Soderhall S: Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 2002;86:356-364.
15. Lindsay R: Modeling the benefits of pamidronate in children with osteogenesis imperfecta. J Clin Invest 2002;110:1239-1241.
16. Falk MJ, Heeger S, Lynch KA, DeCaro R, Bohach D, Gibson KS, Warman ML: intravenous bisphosphonate therapy in children with osteogenesis imperfecta. Pediatrics 2003;111:573-578.
17. Zacharin M, Bateman J: Pamidronate treatment of osteogenesis imperfecta - lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab 2002;15:163-174.
18. DiMeglio LA, Ford L, McClintock C, Peacock M: Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 2004;35:1038-1045.
19. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA: The Effect of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993;92:2577-2586.
20. Pizones J, Plotkin H, ParraGarcia JI, Alvares P, Gutierrez P, Bueno A, Fernandez-Arroyo A: Bone healing in children with osteogenesis imperfecta treated with bisphosphonates. J Pediatr Orthop 2005;25:332-335.
21. Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH: Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19:1779-1786.
22. SempéM: Auxologie méthode et séquences. Paris, Printel, 1979.
23. Bleck EE: Nonoperative treatment of osteogenesis imperfecta: orthotic and mobility management. Clin Orthop Relat Res 1981;159:111-122.
24. Srivastava T, Alon US: Bisphosphonates: from grandparents to grandchildren. Clin Pediatr 1999;38:687-702.
25. Davie MW, Haddway MJ: Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child 1974;70:331-334.
26. Lund AM, Molgaard C, Muller J, Skovby F: Bone mineral content and collagen defects in osteogenesis imperfecta. Acta Paediatr 1999;88:1083-1088.
27. Plotkin H, Rauch F, Bishop NJ, Monpetit K, Ruck-Gibis J, Travers R, Glorieux FH: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-1850.
28. Zeitlin L, Rauch F, Plotkin H, Glorieux FH: Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. Pediatrics 2003;111:1030-1036.
29. Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH: Osteogenesis imperfecta. Types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism. J Clin Endocrinol Metab 2003;88:986-992.
30. Gamble JG, Rinsky LA, Strudwick J, Bleck EE: Non-union of fractures in children who have osteogenesis imperfecta. J Bone Joint Surg 1988;70:439-443.
31. Rauch F, Travers Rose, Poltkin H, Glorieux FH: The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta. J Clin Invest 2002;110:1293-1299.
32. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S: Bisphosphonate-induced osteopetrosis. N Engl J Med 2003;349:457-463.
33. Munns CF, Rauch F, Mier RJ, et al: Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone 2004;35:231-236.
34. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al: Ostoenecrosis of the jaws associated with the use of bisphophonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-534.
35. Papapoulos SE, Cremers SC: Prolonged bisphosphonate release after treatment in children. N Engl J Med 2007;356:1075.
36. Rauch F, Munns C, Land C, Glorieux FH: Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 2006;91:1268-1274.